Ajertil, A., Jirari Rim, M’Benga. L.-J.K. and El Quessar, A. (2025) Severe and Rare Cerebrovascular Involvement in Systemic Lupus Erythematosus: Case Report and Literature Review. Open Access Library ...

Supporting lupus patients and advocates in Arizona.

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

Patients with lupus nephritis who received hydroxychloroquine demonstrated a significantly lower risk for glomerular ...

Enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor, is superior to placebo in improving mucocutaneous symptoms of cutaneous and systemic lupus, according to data ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...